IL6 and rheumatoid arthritis: In patients with rheumatoid arthritis, there are data to suggest that JAK inhibition significantly improves pain outcomes compared to available biologic disease-modifying anti-rheumatic drugs (DMARDs), whilst IL-6 inhibition may reduce disproportionate articular pain in rheumatoid arthritis patients [116,117].